Actively Recruiting
Efficacy and Safety of Activated Charcoal on Mineral Bone Disorder in Chronic Kidney Disease Patients
Led by Mansoura University · Updated on 2025-08-08
40
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to evaluate the use of activated charcoal in managing hyperphosphatemia, a condition common in patients with end-stage renal disease (ESRD) who are on dialysis. Hyperphosphatemia can contribute to worsening vascular calcification, and current management mainly involves limiting dietary phosphorus and using phosphate binders. Activated charcoal, which is generally well tolerated, is being studied as a possible alternative to conventional phosphate binders in dialysis patients. Participants are randomly assigned to one of two groups: one group receives standard care with calcium-based or non-calcium based phosphate binders such as sevelamer, while the other group receives these standard binders plus oral activated charcoal capsules taken with meals. The study is double-blinded and conducted over 8 weeks to assess the effect of activated charcoal on mineral and bone disorder related to chronic kidney disease. During the study, participants will have their serum phosphorus levels measured to evaluate treatment effects. Researchers will also track the percentage of patients who experience a significant decrease in itching intensity using a numerical rating scale. The study includes safety monitoring and aims to gather data on both efficacy and side effects. Overall participation duration includes screening, treatment, and follow-up during the 8-week trial period.
CONDITIONS
Brief Title
Activated Charcoal Use in Chronic Kidney Disease Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult aged 6518 years with end-stage renal disease (ESRD)
- On stable maintenance hemodialysis three times weekly for at least 6 months
- Receiving phosphate binders according to standard kidney disease protocols
You will not qualify if you...
- Severely malnourished as diagnosed by a dietitian
- Receiving overnight dialysis treatments
- Having primary hyperparathyroidism or persistent parathyroid hormone levels above 800 pg/mL
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 8 weeks
Participants receive standard care therapy with phosphate binders, with some also taking oral activated charcoal capsules with meals to study their effects on mineral bone disorder in chronic kidney disease.
Weekly visits for 8 weeks
Trial Site Locations
Total: 1 location
1
Urology and Nephrology Center
Al Mansurah, Please Select, Egypt
Actively Recruiting
Research Team
B
Basma M. Sayed Ahmed, M.Sc.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here